MedTrace Logo

Treatment of Recurrent Bladder Cancer With Dendritic Cells

NCT04184232 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-01-22

No results posted yet for this study

Summary

Treatment of recurrent bladder cancer with dendritic cells

Conditions

Interventions

BIOLOGICAL

Dendritic cells

Autologous dendritic cells primed with muc-1/wt-1 peptides

OTHER

Standard treatment according to the Clinical protocols

Standard treatment of bladder cancer according to the Clinical protocols

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Hancharou, Dr · Director, the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

  • Alexander V Prokharau, Dr · Head of the chair, Belarusian State Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184232 on ClinicalTrials.gov